Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis
The gut microbiota is involved in the development of the immune system and can modulate the risk for immune-mediated disorders such as multiple sclerosis (MS). Dysbiosis has been demonstrated in MS patients and its restoration by disease-modifying treatments (DMTs) is hypothesized. We aimed to study...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-02-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/3/2720 |
| _version_ | 1797624278553722880 |
|---|---|
| author | Caterina Ferri Massimiliano Castellazzi Nicola Merli Michele Laudisi Elisa Baldin Eleonora Baldi Leonardo Mancabelli Marco Ventura Maura Pugliatti |
| author_facet | Caterina Ferri Massimiliano Castellazzi Nicola Merli Michele Laudisi Elisa Baldin Eleonora Baldi Leonardo Mancabelli Marco Ventura Maura Pugliatti |
| author_sort | Caterina Ferri |
| collection | DOAJ |
| description | The gut microbiota is involved in the development of the immune system and can modulate the risk for immune-mediated disorders such as multiple sclerosis (MS). Dysbiosis has been demonstrated in MS patients and its restoration by disease-modifying treatments (DMTs) is hypothesized. We aimed to study the changes in gut microbiota composition during the first 6 months of treatment with dimethyl fumarate (DMF), an oral DMT, and to identify the microorganisms associated with DMF side effects. We collected and analyzed the gut microbiota of 19 MS patients at baseline and after 1, 3, and 6 months of DMF treatment. We then cross-sectionally compared gut microbiota composition according to the presence of gastrointestinal (GI) symptoms and flushing. Overall, the gut microbiota biodiversity showed no changes over the 6-month follow-up. At the genus level, DMF was associated with decreased <i>Clostridium</i> abundance after 6 months. In subjects reporting side effects, a higher abundance of <i>Streptococcus</i>, <i>Haemophilus</i>, <i>Clostridium</i>, <i>Lachnospira</i>, <i>Blautia</i>, <i>Subdoligranulum</i>, and Tenericutes and lower of <i>Bacteroidetes</i>, <i>Barnesiella</i>, <i>Odoribacter</i>, <i>Akkermansia</i>, and some Proteobacteria families were detected. Our results suggest that gut microbiota may be involved in therapeutic action and side effects of DMF, representing a potential target for improving disease course and DMT tolerability. |
| first_indexed | 2024-03-11T09:40:36Z |
| format | Article |
| id | doaj.art-1e6dce0c02a94733b8895c6af372393c |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T09:40:36Z |
| publishDate | 2023-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-1e6dce0c02a94733b8895c6af372393c2023-11-16T17:01:21ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-02-01243272010.3390/ijms24032720Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple SclerosisCaterina Ferri0Massimiliano Castellazzi1Nicola Merli2Michele Laudisi3Elisa Baldin4Eleonora Baldi5Leonardo Mancabelli6Marco Ventura7Maura Pugliatti8Department of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, ItalyDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, ItalyDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, ItalyDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, ItalyDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, ItalyDepartment of Neuroscience and Rehabilitation, St. Anna University Hospital, 44124 Ferrara, ItalyDepartment of Medicine and Surgery, University of Parma, 43124 Parma, ItalyMicrobiome Research Hub, University of Parma, 43124 Parma, ItalyDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, ItalyThe gut microbiota is involved in the development of the immune system and can modulate the risk for immune-mediated disorders such as multiple sclerosis (MS). Dysbiosis has been demonstrated in MS patients and its restoration by disease-modifying treatments (DMTs) is hypothesized. We aimed to study the changes in gut microbiota composition during the first 6 months of treatment with dimethyl fumarate (DMF), an oral DMT, and to identify the microorganisms associated with DMF side effects. We collected and analyzed the gut microbiota of 19 MS patients at baseline and after 1, 3, and 6 months of DMF treatment. We then cross-sectionally compared gut microbiota composition according to the presence of gastrointestinal (GI) symptoms and flushing. Overall, the gut microbiota biodiversity showed no changes over the 6-month follow-up. At the genus level, DMF was associated with decreased <i>Clostridium</i> abundance after 6 months. In subjects reporting side effects, a higher abundance of <i>Streptococcus</i>, <i>Haemophilus</i>, <i>Clostridium</i>, <i>Lachnospira</i>, <i>Blautia</i>, <i>Subdoligranulum</i>, and Tenericutes and lower of <i>Bacteroidetes</i>, <i>Barnesiella</i>, <i>Odoribacter</i>, <i>Akkermansia</i>, and some Proteobacteria families were detected. Our results suggest that gut microbiota may be involved in therapeutic action and side effects of DMF, representing a potential target for improving disease course and DMT tolerability.https://www.mdpi.com/1422-0067/24/3/2720gut microbiotamultiple sclerosisdimethyl fumarategastrointestinal side effectsflushing<i>Clostridium</i> |
| spellingShingle | Caterina Ferri Massimiliano Castellazzi Nicola Merli Michele Laudisi Elisa Baldin Eleonora Baldi Leonardo Mancabelli Marco Ventura Maura Pugliatti Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis International Journal of Molecular Sciences gut microbiota multiple sclerosis dimethyl fumarate gastrointestinal side effects flushing <i>Clostridium</i> |
| title | Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis |
| title_full | Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis |
| title_fullStr | Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis |
| title_full_unstemmed | Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis |
| title_short | Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis |
| title_sort | gut microbiota changes during dimethyl fumarate treatment in patients with multiple sclerosis |
| topic | gut microbiota multiple sclerosis dimethyl fumarate gastrointestinal side effects flushing <i>Clostridium</i> |
| url | https://www.mdpi.com/1422-0067/24/3/2720 |
| work_keys_str_mv | AT caterinaferri gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT massimilianocastellazzi gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT nicolamerli gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT michelelaudisi gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT elisabaldin gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT eleonorabaldi gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT leonardomancabelli gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT marcoventura gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis AT maurapugliatti gutmicrobiotachangesduringdimethylfumaratetreatmentinpatientswithmultiplesclerosis |